FOXO4-DRI vs NAD+
FOXO4-DRI (Senolytic peptide) and NAD+ (Cellular coenzyme (dinucleotide)) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | FOXO4-DRI | NAD+ |
|---|---|---|
| Compound class | Senolytic peptide | Cellular coenzyme (dinucleotide) |
| Research category | Longevity & Cellular | Longevity & Cellular |
| Length (amino acids) | Not documented | Not documented |
| Molecular weight | Not documented | 663.43 g/mol (free acid) |
| Half-life | Not documented | Not documented |
| Origin | FOXO4-DRI is a synthetic, retro-inverso (D-amino acid) peptide designed by researchers (notably from the group of Peter de Keizer) based on the FOXO4 sequence that interacts with p53. It was engineered as a proof-of-concept senolytic to target senescent cells. | Nicotinamide adenine dinucleotide (NAD+) is a naturally occurring coenzyme present in all living cells, first described in the early 20th century in the context of fermentation and cellular respiration. It is not a peptide but a dinucleotide composed of a nicotinamide moiety and an adenine moiety joined through ribose and phosphate groups. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How FOXO4-DRI works
FOXO4-DRI is designed to competitively interfere with the interaction between FOXO4 and the tumor suppressor p53 in senescent cells. By disrupting FOXO4-p53 binding, it is reported to release p53 from the nucleus, triggering apoptosis preferentially in senescent cells (a senolytic effect). This mechanism was demonstrated in cell and mouse models; the retro-inverso D-amino acid design was intended to improve peptide stability.
How NAD+ works
NAD+ functions as a central redox cofactor, cycling between its oxidized (NAD+) and reduced (NADH) forms to shuttle electrons in glycolysis, the citric acid cycle, and oxidative phosphorylation. Beyond redox chemistry, NAD+ is a required substrate for enzymes that consume it, including sirtuins (NAD+-dependent deacylases), poly(ADP-ribose) polymerases (PARPs) involved in DNA repair, and CD38. Cellular NAD+ levels have been reported to decline with age in various tissues, which is a focus of aging research. It is synthesized de novo from tryptophan and through salvage pathways from precursors such as nicotinamide, nicotinic acid, and nicotinamide riboside.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
FOXO4-DRI
NAD+
What sets each apart
FOXO4-DRI
FOXO4-DRI is the only senolytic in this set, working by clearing senescent cells via FOXO4-p53 disruption, rather than acting on immune, mitochondrial, or pineal pathways.
NAD+
Unlike the peptides in this category, NAD+ is a small-molecule coenzyme central to redox metabolism rather than a signaling peptide, and it is studied primarily via precursor supplementation.
Frequently asked questions
What is FOXO4-DRI?
FOXO4-DRI is a synthetic senolytic peptide designed as a D-retro-inverso (DRI) version of a FOXO4 fragment. It is studied for selectively clearing senescent ("zombie") cells by disrupting the FOXO4-p53 interaction, and it is a research-stage compound with no human clinical trials.
How does FOXO4-DRI work as a senolytic?
In senescent cells, FOXO4 binds and sequesters p53 in the nucleus, blocking apoptosis. FOXO4-DRI competitively disrupts this FOXO4-p53 interaction, releasing p53 to trigger apoptosis preferentially in senescent cells while reportedly sparing healthy cells in preclinical models.
What does 'D-retro-inverso' mean for this peptide?
D-retro-inverso means the sequence is reversed (retro) and built from D-amino acids instead of natural L-amino acids (inverso), which preserves the overall side-chain topology while greatly increasing resistance to proteolysis. This design extends functional stability from minutes to hours, enabling systemic dosing in preclinical models.
What is NAD+ and what is it studied for?
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism, redox reactions, and as a substrate for sirtuins and PARP enzymes involved in DNA repair. It is studied in models of aging, mitochondrial function, metabolic decline, and neuroprotection, where tissue NAD+ levels fall with age. It is a naturally occurring coenzyme, not a peptide.
Is NAD+ a peptide?
No. NAD+ is a dinucleotide coenzyme composed of two nucleotides (one bearing adenine, the other nicotinamide) joined through phosphate groups, not a chain of amino acids. It is grouped in longevity research catalogs alongside peptides because of its role in aging and mitochondrial studies, but it is a distinct chemical class.
How does NAD+ differ from precursors like NMN and NR?
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors that cells convert into NAD+, whereas NAD+ is the finished coenzyme. Precursors are commonly studied as oral routes to raise intracellular NAD+, while NAD+ itself is studied via IV or subcutaneous routes in research settings. Direct cellular uptake of intact NAD+ is a subject of ongoing research.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.